ZA201005222B - Use of anti-connexon polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions - Google Patents

Use of anti-connexon polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions

Info

Publication number
ZA201005222B
ZA201005222B ZA2010/05222A ZA201005222A ZA201005222B ZA 201005222 B ZA201005222 B ZA 201005222B ZA 2010/05222 A ZA2010/05222 A ZA 2010/05222A ZA 201005222 A ZA201005222 A ZA 201005222A ZA 201005222 B ZA201005222 B ZA 201005222B
Authority
ZA
South Africa
Prior art keywords
agent
treatment
combination
fibrotic conditions
connexin polynucleotide
Prior art date
Application number
ZA2010/05222A
Other languages
English (en)
Inventor
Bradford J Duft
Original Assignee
Coda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coda Therapeutics Inc filed Critical Coda Therapeutics Inc
Publication of ZA201005222B publication Critical patent/ZA201005222B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
ZA2010/05222A 2007-12-21 2010-07-21 Use of anti-connexon polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions ZA201005222B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US888607P 2007-12-21 2007-12-21
PCT/US2008/014026 WO2009085275A2 (en) 2007-12-21 2008-12-22 Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions

Publications (1)

Publication Number Publication Date
ZA201005222B true ZA201005222B (en) 2011-07-27

Family

ID=40824959

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/05222A ZA201005222B (en) 2007-12-21 2010-07-21 Use of anti-connexon polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions

Country Status (7)

Country Link
US (1) US20110092449A1 (OSRAM)
EP (1) EP2237795A2 (OSRAM)
JP (2) JP2011507861A (OSRAM)
AU (1) AU2008343756A1 (OSRAM)
CA (1) CA2710387A1 (OSRAM)
WO (1) WO2009085275A2 (OSRAM)
ZA (1) ZA201005222B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006257283A1 (en) 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
DK2049123T4 (en) 2006-08-03 2016-11-28 Horizon Pharma Ag LATE discharge-glucocorticoid treatment of rheumatoid ILLNESS
WO2009075882A2 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
JP2011507857A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 線維症性の状態の処置のためのコネキシン４３の阻害剤の使用
US8618175B2 (en) * 2010-07-19 2013-12-31 Brussels Ventures Corp. Ultrasound medical gel composition etherified hydroxyethylcellulose
JP6185937B2 (ja) 2012-03-01 2017-08-23 ファーストストリング・リサーチ・インコーポレイテッドＦｉｒｓｔｓｔｒｉｎｇ Ｒｅｓｅａｒｃｈ，Ｉｎｃ． アルファコネキシンｃ末端（ａｃｔ）ペプチド含有局所用ゲル剤
US10465188B2 (en) 2014-08-22 2019-11-05 Auckland Uniservices Limited Channel modulators
CA3050082A1 (en) 2016-04-04 2017-10-12 Omeza LLC Fish oil topical composition
CN109414475A (zh) * 2016-05-03 2019-03-01 奥克兰大学 新型肽和肽模拟物
WO2018199777A1 (en) 2017-04-28 2018-11-01 Auckland Uniservices Limited Methods of treatment and novel constructs
MX2022012656A (es) * 2020-04-07 2022-11-07 Firststring Res Inc Composiciones y metodos para tratar complicaciones de infecciones virales y otros trastornos respiratorios.
CN116710474A (zh) 2020-10-22 2023-09-05 撒凯尔生物公司 肽制剂及其眼科用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) * 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4861757A (en) * 1986-11-14 1989-08-29 Institute Of Molecular Biology Wound healing and bone regeneration using PDGF and IGF-I
JPH0539594Y2 (OSRAM) * 1988-08-05 1993-10-07
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US6752987B1 (en) * 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US6458590B1 (en) * 1997-08-07 2002-10-01 The United States Of America, As Represented By The Department Of Health And Human Services Methods and compositions for treatment of restenosis
WO1999029858A1 (en) * 1997-12-09 1999-06-17 Children's Medical Center Corporation Soluble inhibitors of vascular endothelial growth factor and use thereof
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
ATE533515T1 (de) * 1999-01-27 2011-12-15 Coda Therapeutics Inc Formulierungen enthaltend antisense nukleotide spezifisch für connexine
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
WO2003032964A2 (en) * 2001-10-17 2003-04-24 University Of Wales College Of Medecine Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
JP2005516054A (ja) * 2002-01-29 2005-06-02 ワイス コネキシンヘミチャンネルを調節する組成物及びその方法
US20030215424A1 (en) * 2002-05-15 2003-11-20 Seul Kyung Hwan Method of modulating angiogenesis
AU2003265866A1 (en) * 2002-09-03 2004-03-29 Vit Lauermann Targeted release
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US8034789B2 (en) * 2003-12-03 2011-10-11 Coda Therapeutics, Inc. Antisense compounds targeted to connexins and methods of use thereof
AU2006257283A1 (en) * 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
RU2542471C2 (ru) * 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
CA2672220A1 (en) * 2006-12-11 2008-06-19 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
WO2009075882A2 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments

Also Published As

Publication number Publication date
WO2009085275A3 (en) 2009-10-01
EP2237795A2 (en) 2010-10-13
US20110092449A1 (en) 2011-04-21
JP2015083606A (ja) 2015-04-30
AU2008343756A1 (en) 2009-07-09
WO2009085275A2 (en) 2009-07-09
JP2011507861A (ja) 2011-03-10
CA2710387A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
ZA201005222B (en) Use of anti-connexon polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
IL262838A (en) Guanylate cyclase agonists for use in the treatment of hypercholesterolemia
IL230683A0 (en) dpp-iv inhibitors for use in the treatment of nafld
PL1975226T3 (pl) Płynna kompozycja do obróbki
ZA201200373B (en) Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
ZA201005218B (en) Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions
IL217562A0 (en) Treatment with alpha 7-selective ligands
ZA201005215B (en) Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions
ZA200903837B (en) Use of 3-Alpha-androstanediol, optionally in combination with A-5-HT1A agonist, in the treatment of sexual dysfunction
EP2307052A4 (en) ANTI-BETA-2-MICROGLOBULIN AGENTS AND THEIR USE
PT2310042E (pt) Uso de pasireotido para o tratamento de hipoglicemia hiperinsulinémica endógena
IL218851A0 (en) Use of dimiracetam in the treatment of chronic pain
IL207127A0 (en) Aldh-2 inhibitors in the treatment of addiction
IL216919A0 (en) Diffusion enhancing compounds and their use alone or with thrombolytics
EG26571A (en) Its composition consists of a treatment component and a carrier for water treatment
IL204668A0 (en) Use of sulfonyl - substituted 2 - sulfonylaminobenzoic acid n - phenylamides in the treatment of pain
GB0719771D0 (en) Dexanabinol in combination with inhibitors of BRAF or MEK for the treatment of melanoma
GB0714500D0 (en) composition and treatment
ZA201206853B (en) Composition for use in water treatment
SI2588093T1 (sl) Tapentadol za uporabo pri zdravljenju sindroma razdražljivega črevesja
ZA200807156B (en) Liquid treatment composition
GB0820562D0 (en) Novel use and treatment
GB0722338D0 (en) Novel use and treatment
PL2053120T3 (pl) Kształtka środka piorącego lub czyszczącego o strukturze reliefowej, dającej się barwić
GB0705274D0 (en) Suit for use in contact with water